A class action lawsuit has been filed against uniQure NV on behalf of investors who bought or acquired its securities between September 24, 2025 and October 31, 2025. The complaint alleges the company misled investors about the effectiveness of its AMT-130 gene therapy candidate and the likelihood of accelerated FDA approval, and says later disclosures about unresolved FDA agreement and an uncertain BLA timeline contributed to a sharp share-price decline. Investors have until April 13, 2026 to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via Newsfile (Ref. ID: 202602260921NEWSFILECNPR____20260226_285397_1) on February 26, 2026, and is solely responsible for the information contained therein.